Careers at Antiverse
Antiverse
Antiverse is a new type of antibody discovery company accelerating drug development.
The Antiverse platform exists at the intersection of antibody discovery and machine learning to enable breakthroughs to happen more quickly and cost-effectively.
Founded in 2017, Antiverse is dedicated to engineering the future of drug development to change the course of people's lives. The company is headquartered in Cardiff, Wales.
Join us to grow and evolve with a company transforming drug discovery!
Our Headquarters
Our headquarters is based in Cardiff, UK.
Our primary laboratory and office facilities are based here, however, Antiverse is proud to support a team of global engineers, biologists and scientists.
Values
-
People first
We work to make things better for everyone: both on a societal level and a personal level. We will thrive, as a team, as a company and as a society by combining smartness with thoughtfulness across everything we do.
-
Rigour and Agility
We move fast and innovate in our thinking, yet combine this agility with utter rigour and robustness. We are dedicated to delivering rock-solid solutions.
-
Interdisciplinarity
An ugly word for a beautiful idea. Our interdisciplinary approach goes deeper than our science. We believe that the best ideas and the most interesting conversations often come from synthesising diverse expertise and experiences.
-
Dignity and Nurture
We fundamentally believe in the value of each individual and the worth of their contribution, regardless of the outcome. We thrive best in a nurturing environment, and everything we do is committed to building a supportive culture.
-
Go where there's a need
We have the potential to transform lives. We will not let ourselves be sidetracked in this calling. We will not fail those whose future we can save.
About Antiverse
Antiverse was founded by Ben Holland, Murat Tunaboylu and Rowina Westermeir at the Deep Science Ventures Accelerator Programme in 2017. Their objective was to create new enabling technologies in antibody discovery using artificial intelligence that allows for the creation of new therapies against the industry's most challenging targets. Since then, Antiverse has worked with five companies in antibody discovery programmes aimed at several GPCRs, Ion Channels and other challenging targets. In addition, we are developing our own internal pipeline, and have raised around $10.1 million.